Viveve Announces Second Quarter 2017 Financial Results and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
61
Viveve Announces Second Quarter 2017 Financial Results and Strategic Partnership with InControl Medical, LLC

ENGLEWOOD, CO --(Marketwired - August 10, 2017) - Viveve Medical Inc. ("Viveve") ( NASDAQ : VIVE ), a medical technology company focused on women's health, today reported financial results for the second quarter ended June 30, 2017 and announced it has entered into an exclusive distribution agreement and strategic investment with InControl Medical, LLC ("InControl Medical") of Brookfield, Wisconsin, a medical device company that manufactures and distributes devices to treat various incontinence conditions and strengthen pelvic floor muscles.

"During the second quarter, we continued to achieve our commercial objectives and experienced growing demand for our innovative technology in the U.S. We also reached a number of important milestones that support our global commercialization strategy," said Patricia Scheller, chief executive officer and director of Viveve.

Q2 2017 Business Highlights

  • Recognized $3.1 million in total revenue for the second quarter of 2017
  • Achieved record number of global treatment tip sales of approximately 3,300 units -- a 46% increase over the first quarter of 2017
  • Recorded strong U.S. capital sales with 60% of the second quarter of 2017 system sales attributed to the U.S. market
  • Secured $30 million debt financing to support continued global expansion and commercial operations
  • Selected for inclusion in the 2017 Russell 2000 Index
  • Opened new corporate headquarters in Englewood, Colorado
  • Expanded U.S. sales organization to 23 total in-field representatives to meet growing demand and customer support
  • Received regulatory approval in South Korea for expanded indication to include vaginal laxity

Q2 2017 Financial Results Revenue for the second quarter of 2017 totaled $3,076,000 from the sale of 45 systems, 27 of which were sold in the U.S. market through direct sales, and approximately 3,300 treatment tips, compared to revenue of $1,556,000 for the same period in 2016, an increase of almost 100% year over year. Sales in the second quarter of 2016 included 40 systems and a much smaller quantity of treatment tips that were sold entirely outside the U.S. to Viveve distribution partners.

Gross profit for the second quarter of 2017 was $1,239,000, or 40% of revenue, compared to gross profit of $534,000, or 34% of revenue, for the same period in 2016. The increase in gross profit was primarily due to sales of 45 systems in the second quarter of 2017, which included 27 systems sold in the U.S. market through direct sales.

Total operating expenses for the second quarter of 2017 were $10,302,000, up from $5,078,000 in the same period in 2016, primarily as a result of increased costs to support U.S. commercialization and expansion into new international markets, research and development efforts, and strategies to protect our intellectual property, as well as other general corporate expenses. Selling, general and administrative expenses for the second quarter of 2017 increased primarily due to increased sales and marketing efforts to build brand and market awareness, expenses associated with being a public company.

Net loss for the second quarter of 2017 was $10,425,000, or a loss of $0.54 per share, compared with a net loss of $5,316,000, or a loss of $0.66 per share, for the same period in 2016.

Cash and cash equivalents were $31,060,000 as of June 30, 2017, an increase of $22,974,000 from $8,086,000 as of December 31, 2016.

Viveve now has an installed base of 304 systems worldwide, 87 of which were sold in the first half of 2017.

InControl Medical Distribution Agreement and Strategic Investment "Completing an agreement with InControl Medical represents a significant opportunity for Viveve in the U.S. professional healthcare market. The addition of InControl Medical's FDA cleared medical devices for stress, urge, and mixed incontinence as well as their products to improve pelvic floor strength enhances our portfolio with a range of high quality products that are used by healthcare professionals within Viveve's currently targeted specialties," said Ms. Scheller.

The finalized agreement grants Viveve exclusive distribution rights to all InControl Medical products for sale to healthcare providers in the United States. Viveve will also make a $2.5 million equity investment in InControl Medical.

"In addition to InControl Medical's innovative devices to treat incontinence, their products aimed at improving patients' pelvic floor strength and health complement the effectiveness of Viveve's Geneveve treatment, that currently has regulatory clearance or approval in over 50 countries for the treatment of vaginal laxity and/or the improvement of sexual function. In the United States, the Viveve System is cleared by the FDA for general surgical procedures for electrocoagulation and hemostasis," Ms. Scheller continued.

"We are pleased with the opportunity to partner with Viveve to enable wider distribution of our clinically proven devices to U.S. medical professionals who can help the millions of patients suffering from pelvic floor and related incontinence conditions. Our hope is that these products will allow more women to have better control and an improved quality of life. Viveve and InControl share a dedicated commitment to advancing solutions for women's health," said Herschel Peddicord, founder and chief executive officer of InControl Medical.

According to the National Association for Incontinence, an estimated 25 million adult Americans suffer from some form of urinary incontinence, and 75-80% of people affected are women. The proven-effective products by InControl Medical further expand the Viveve focus on therapeutic solutions that effectively address common conditions and unmet needs in women's health.

Conference Call Information The company will host a live conference call at 5:00 p.m. ET today. The conference call can be accessed at to http://dpregister.com/10110844 . The dial-in telephone number will be provided upon registration either in advance of or at the time of the conference call. The conference call will be archived on the company's website at http://ir.viveve.com/ir-calendar .

About Viveve Viveve Medical, Inc. is a women's health and wellness company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System, that delivers the GENEVEVE™ treatment, incorporates clinically-proven cryogen-cooled, monopolar radiofrequency (CMRF) energy-based technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate robust neocollagenesis in one 30-minute in-office session.

In the United States, the Viveve System is cleared by the FDA for general surgical procedures for electrocoagulation and hemostasis. Consistent with approvals in many countries internationally, Viveve is currently in the process of submitting an IDE to the FDA to conduct a pivotal study on use of the device in the United States for improvement in sexual function. For more information visit Viveve's website at www.viveve.com .

About InControl Medical InControl Medical, LLC is an innovative medical device company with a drive to establish its cost-effective, non-invasive devices as standard of care for male and female bladder and bowel leakage. The Company believes that first-line treatment should focus on improving the strength and support of the pelvic floor, restoring continence naturally. InControl Medical is the only company with treatment solutions for all types of incontinence in both men and women and the only company with a single device treatment for female stress, urge, and mixed urinary incontinence. The company has sold over 64,000 devices worldwide. For more information visit the InControl Medical website at www.incontrolmedical.com .

Safe Harbor Statement All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov . Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Viveve is a registered trademark of Viveve, Inc. Geneveve is a trademark of Viveve, Inc.

   
VIVEVE MEDICAL, INC.  
CONDENSED CONSOLIDATED BALANCE SHEETS  
(in thousands, except share data)  
(unaudited)  
                 
      June 30,       December 31,  
      2017       2016  
ASSETS                
Current assets:                
  Cash and cash equivalents   $ 31,060     $ 8,086  
  Accounts receivable     3,800       2,091  
  Inventory     2,043       2,687  
  Prepaid expenses and other current assets     1,888       1,066  
      Total current assets     38,791       13,930  
Property and equipment, net     987       483  
Other assets     132       136  
      Total assets   $ 39,910     $ 14,549  
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)                
Current liabilities:                
  Accounts payable   $ 3,344     $ 3,086  
  Accrued liabilities     2,181       2,186  
  Note payable, current portion     -       1,867  
      Total current liabilities     5,525       7,139  
Note payable, noncurrent portion     18,392       7,762  
Other noncurrent liabilities     -       53  
      Total liabilities     23,917       14,954  
Stockholders' equity (deficit):                
  Common stock and paid in capital     101,735       68,217  
  Accumulated deficit     (85,742 )     (68,622 )
      Total stockholders' equity (deficit)     15,993       (405 )
      Total liabilities and stockholders' equity (deficit)   $ 39,910     $ 14,549  
                 
                 
                                 
VIVEVE MEDICAL, INC.  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
(in thousands, except share and per share data)  
(unaudited)  
                         
    Three Months Ended     Six Months Ended  
    June 30,     June 30,  
    2017     2016     2017     2016  
                                 
Revenue   $ 3,076     $ 1,556     $ 6,117     $ 2,840  
Cost of revenue     1,837       1,022       3,456       1,958  
  Gross profit     1,239       534       2,661       882  
                                 
Operating expenses:                                
Research and development     3,440       2,463       5,828       4,259  
Selling, general and administrative     6,862       2,615       12,312       5,163  
  Total operating expenses     10,302       5,078       18,140       9,422  
  Loss from operations     (9,063 )     (4,544 )     (15,479 )     (8,540 )
Interest expense, net     (1,345 )     (765 )     (1,608 )     (873 )
Other expense, net     (17 )     (7 )     (33 )     (9 )
  Comprehensive and net loss   $ (10,425 )   $ (5,316 )   $ (17,120 )   $ (9,422 )
                                 
Net loss per share:                                
  Basic and diluted   $ (0.54 )   $ (0.66 )   $ (1.10 )   $ (1.21 )
                                 
Weighted average shares used in computing net loss per common share                                
  Basic and diluted     19,373,322       8,080,737       15,539,840       7,786,889  
                                 

Investor Relations contact: Amato and Partners, LLC 90 Park Avenue, 17th Floor New York, NY 10016 (212) 430-0360 admin@amatoandpartners.com Media contact: Sara Zelkovic Berry & Company Public Relations (212) 253-8881 szelkovic@berrypr.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 286

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 238

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 131

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 0

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 0

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Elon Musk Reflects on PayPal Departure: Insights and Implications

Updated Category News Views 269

Elon Musk's PayPal Exit: A Twist of Fate Elon Musk, the CEO of Tesla Inc. (NASDAQ: TSLA) and SpaceX, recently spoke candidly about his departure from PayPal Holdings Inc. (NASDAQ: PYPL). He described the situation as a "palace coup,” asserting that significant members of the executive team conspired against him. According to Musk, the decision to push him out was met...

Continue Reading
Stellantis Approves Major Dividend Distribution and Board Appointments

Updated Category News Views 210

Stellantis Annual General Meeting Outcomes Stellantis N.V. recently held a significant Annual General Meeting where notable resolutions received the green light from shareholders. The meeting, attended in person and streamed online, showcased Stellantis' commitment to engaging with its stakeholders. Dividend Distribution Approved One of the key highlights was the approval...

Continue Reading
Smart Strategies to Stay Safe During Summer Storms

Updated Category News Views 259

Stay Prepared for Summer Storms Be Prepared & Keep Safety in Mind, Says the Outdoor Power Equipment Institute As we enter the summer storm season, it is crucial to equip ourselves with essential outdoor power equipment to withstand potential disruptions. The Outdoor Power Equipment Institute emphasizes that being proactive can help minimize damage caused by high winds,...

Continue Reading
NativState Delivers Verified Carbon Credits from New Projects

Updated Category News Views 136

NativState's Latest Milestone in Carbon Credit Verification In a significant achievement for environmental sustainability, NativState, LLC, based in Conway, Arkansas, has successfully verified and released high-quality carbon credits from two groundbreaking projects. These efforts highlight the company's commitment to fostering nature-based solutions that combat climate...

Continue Reading
Qatar Airways and QNB Group Forge New Ground in Financing

Updated Category News Views 725

Qatar Airways and QNB Group Join Forces for Strategic Financing Recently, the Qatar Airways Group secured a significant loan facility with several local banks amounting to QAR 4.5 billion. This remarkable financial arrangement represents a strategic step forward for Qatar Airways, aligning with the national vision to promote sustainable economic growth in the region....

Continue Reading